Lexicon Pharmaceuticals, Inc. (LXRX)
收市後：
| 前收市價 | 1.0900 |
| 開市 | 1.0900 |
| 買盤 | 1.0100 x 2900 |
| 賣出價 | 1.0600 x 1200 |
| 今日波幅 | 1.0000 - 1.0992 |
| 52 週波幅 | 1.0000 - 3.7900 |
| 成交量 | |
| 平均成交量 | 1,562,966 |
| 市值 | 249.823M |
| Beta 值 (5 年，每月) | 1.17 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.6800 |
| 業績公佈日 | 2023年11月07日 - 2023年11月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 5.55 |
BenzingaLexicon Pharma's Pain Candidate Fails In Postherpetic Neuralgia Study
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced the topline results of RELIEF-PHN-1 Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia, a lasting pain in the areas of the skin that had shingles. LX9211 achieved a reduction in average daily pain score (ADPS) of 2.42 from baseline at week six compared to a reduction of 1.62 in the placebo arm, with a placebo-adjusted difference of 0.80 (p=0.12). Although these results did not reach statistical significance on the study's prima
BenzingaLexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo run-off following the initial 6-week treatment period. The data exhibited consistent and statistically significant treatment-period benefits in measures of particular importance in painful diabetic neuropathy (also k
